Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
INNV vs OSCR vs ALHC vs UNH vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
INNV vs OSCR vs ALHC vs UNH vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $1.10B | $5.41B | $3.73B | $335.60B | $111.40B |
| Revenue (TTM) | $946M | $13.30B | $4.26B | $449.71B | $407.90B |
| Net Income (TTM) | $-22M | $-39M | $20M | $12.04B | $2.93B |
| Gross Margin | 14.8% | 17.4% | 9.0% | 18.8% | 13.9% |
| Operating Margin | 1.5% | 0.1% | 0.8% | 4.2% | 1.5% |
| Forward P/E | 32.0x | 34.7x | 140.9x | 20.2x | 12.2x |
| Total Debt | $101M | $430M | $338M | $78.39B | $93.59B |
| Cash & Equiv. | $64M | $2.77B | $578M | $24.36B | $8.51B |
INNV vs OSCR vs ALHC vs UNH vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| InnovAge Holding Co… (INNV) | 100 | 31.3 | -68.7% |
| Oscar Health, Inc. (OSCR) | 100 | 77.6 | -22.4% |
| Alignment Healthcar… (ALHC) | 100 | 83.2 | -16.8% |
| UnitedHealth Group … (UNH) | 100 | 99.4 | -0.6% |
| CVS Health Corporat… (CVS) | 100 | 116.1 | +16.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: INNV vs OSCR vs ALHC vs UNH vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
INNV ranks third and is worth considering specifically for momentum.
- +147.9% vs UNH's -3.2%
Among these 5 stocks, OSCR doesn't own a clear edge in any measured category.
ALHC is the clearest fit if your priority is growth exposure.
- Rev growth 46.1%, EPS growth 99.4%, 3Y rev CAGR 40.2%
- 46.1% revenue growth vs CVS's 7.8%
UNH carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 220.6% 10Y total return vs CVS's 3.5%
- 2.7% margin vs INNV's -2.3%
- 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (3 stocks pay no dividend)
- 3.9% ROA vs INNV's -4.1%, ROIC 9.2% vs -6.8%
CVS is the #2 pick in this set and the best alternative if income & stability and sleep-well-at-night is your priority.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Lower volatility, beta 0.05, current ratio 0.84x
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Lower P/E (12.2x vs 20.2x)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 46.1% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (12.2x vs 20.2x) | |
| Quality / Margins | 2.7% margin vs INNV's -2.3% | |
| Stability / Safety | Beta 0.05 vs OSCR's 1.84 | |
| Dividends | 2.4% yield, 25-year raise streak, vs CVS's 3.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +147.9% vs UNH's -3.2% | |
| Efficiency (ROA) | 3.9% ROA vs INNV's -4.1%, ROIC 9.2% vs -6.8% |
INNV vs OSCR vs ALHC vs UNH vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
INNV vs OSCR vs ALHC vs UNH vs CVS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNH leads in 2 of 6 categories
CVS leads 2 • INNV leads 0 • OSCR leads 0 • ALHC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNH leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 475.4x INNV's $946M. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to INNV's -2.3%. On growth, OSCR holds the edge at +52.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $946M | $13.3B | $4.3B | $449.7B | $407.9B |
| EBITDAEarnings before interest/tax | $4M | $40M | $66M | $23.2B | $10.5B |
| Net IncomeAfter-tax profit | -$22M | -$39M | $20M | $12.0B | $2.9B |
| Free Cash FlowCash after capex | $39M | $2.8B | $237M | $19.7B | $7.4B |
| Gross MarginGross profit ÷ Revenue | +14.8% | +17.4% | +9.0% | +18.8% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +1.5% | +0.1% | +0.8% | +4.2% | +1.5% |
| Net MarginNet income ÷ Revenue | -2.3% | -0.3% | +0.5% | +2.7% | +0.7% |
| FCF MarginFCF ÷ Revenue | +4.1% | +21.0% | +5.6% | +4.4% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +15.5% | +52.6% | +33.3% | +2.0% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -161.3% | +125.0% | +2.1% | +0.7% | +63.1% |
Valuation Metrics
CVS leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 27.9x trailing earnings, UNH trades at a 56% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than ALHC's 77.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.1B | $5.4B | $3.7B | $335.6B | $111.4B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $3.1B | $3.5B | $389.6B | $196.5B |
| Trailing P/EPrice ÷ TTM EPS | -36.73x | -12.35x | -4932.43x | 27.95x | 62.81x |
| Forward P/EPrice ÷ next-FY EPS est. | 32.03x | 34.65x | 140.93x | 20.19x | 12.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 77.12x | 16.70x | 13.11x |
| Price / SalesMarket cap ÷ Revenue | 1.28x | 0.46x | 0.94x | 0.75x | 0.28x |
| Price / BookPrice ÷ Book value/share | 4.16x | 5.58x | 20.16x | 3.31x | 1.47x |
| Price / FCFMarket cap ÷ FCF | 41.22x | 5.11x | 32.95x | 20.88x | 14.27x |
Profitability & Efficiency
UNH leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
UNH delivers a 11.5% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-8 for INNV. INNV carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to ALHC's 1.89x. On the Piotroski fundamental quality scale (0–9), INNV scores 6/9 vs OSCR's 4/9, reflecting solid financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -8.2% | -3.3% | +11.5% | +11.5% | +3.9% |
| ROA (TTM)Return on assets | -4.1% | -0.6% | +1.8% | +3.9% | +1.1% |
| ROICReturn on invested capital | -6.8% | — | — | +9.2% | +5.0% |
| ROCEReturn on capital employed | -7.1% | -25.3% | +2.9% | +9.7% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.38x | 0.44x | 1.89x | 0.77x | 1.24x |
| Net DebtTotal debt minus cash | $37M | -$2.3B | -$240M | $54.0B | $85.1B |
| Cash & Equiv.Liquid assets | $64M | $2.8B | $578M | $24.4B | $8.5B |
| Total DebtShort + long-term debt | $101M | $430M | $338M | $78.4B | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | 5.96x | -0.57x | 1.27x | 4.71x | 2.11x |
Total Returns (Dividends Reinvested)
Evenly matched — INNV and OSCR each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,700 today (with dividends reinvested), compared to $3,150 for INNV. Over the past 12 months, INNV leads with a +147.9% total return vs UNH's -3.2%. The 3-year compound annual growth rate (CAGR) favors OSCR at 40.5% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +55.7% | +39.4% | -9.7% | +10.6% | +10.6% |
| 1-Year ReturnPast 12 months | +147.9% | +22.6% | +17.6% | -3.2% | +34.7% |
| 3-Year ReturnCumulative with dividends | +24.5% | +177.5% | +152.4% | -19.9% | +36.6% |
| 5-Year ReturnCumulative with dividends | -68.5% | -7.3% | -22.7% | -2.6% | +17.0% |
| 10-Year ReturnCumulative with dividends | -66.6% | -40.0% | +5.4% | +220.6% | +3.5% |
| CAGR (3Y)Annualised 3-year return | +7.6% | +40.5% | +36.2% | -7.1% | +11.0% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than OSCR's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs INNV's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.66x | 1.84x | 0.75x | 0.59x | 0.05x |
| 52-Week HighHighest price in past year | $10.68 | $23.80 | $23.87 | $395.52 | $88.63 |
| 52-Week LowLowest price in past year | $2.85 | $10.69 | $11.63 | $234.60 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +87.7% | +76.5% | +93.5% | +98.5% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 78.5 | 37.3 | 75.9 | 69.3 |
| Avg Volume (50D)Average daily shares traded | 291K | 6.5M | 3.6M | 7.9M | 7.4M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: INNV as "Hold", OSCR as "Hold", ALHC as "Buy", UNH as "Buy", CVS as "Buy". Consensus price targets imply 36.1% upside for ALHC (target: $25) vs -19.7% for OSCR (target: $17). For income investors, CVS offers the higher dividend yield at 3.06% vs UNH's 2.35%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.80 | $16.75 | $24.83 | $385.43 | $95.20 |
| # AnalystsCovering analysts | 8 | 11 | 16 | 52 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +2.4% | +3.1% |
| Dividend StreakConsecutive years of raises | 0 | — | — | 25 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $8.70 | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | 0.0% | +1.7% | 0.0% |
UNH leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Valuation Metrics, Risk & Volatility). 2 tied.
INNV vs OSCR vs ALHC vs UNH vs CVS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is INNV or OSCR or ALHC or UNH or CVS a better buy right now?
For growth investors, Alignment Healthcare, Inc.
(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). UnitedHealth Group Incorporated (UNH) offers the better valuation at 27. 9x trailing P/E (20. 2x forward), making it the more compelling value choice. Analysts rate Alignment Healthcare, Inc. (ALHC) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — INNV or OSCR or ALHC or UNH or CVS?
On trailing P/E, UnitedHealth Group Incorporated (UNH) is the cheapest at 27.
9x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — INNV or OSCR or ALHC or UNH or CVS?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +17.
0%, compared to -68. 5% for InnovAge Holding Corp. (INNV). Over 10 years, the gap is even starker: UNH returned +220. 6% versus INNV's -66. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — INNV or OSCR or ALHC or UNH or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 3531% more volatile than CVS relative to the S&P 500. On balance sheet safety, InnovAge Holding Corp. (INNV) carries a lower debt/equity ratio of 38% versus 189% for Alignment Healthcare, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — INNV or OSCR or ALHC or UNH or CVS?
By revenue growth (latest reported year), Alignment Healthcare, Inc.
(ALHC) is pulling ahead at 46. 1% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — INNV or OSCR or ALHC or UNH or CVS?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -3. 8% for Oscar Health, Inc. — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -3. 5% for INNV. At the gross margin level — before operating expenses — INNV leads at 68. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is INNV or OSCR or ALHC or UNH or CVS more undervalued right now?
On forward earnings alone, CVS Health Corporation (CVS) trades at 12.
2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 128. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALHC: 36. 1% to $24. 83.
08Which pays a better dividend — INNV or OSCR or ALHC or UNH or CVS?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield) pay a dividend. INNV, OSCR, ALHC do not pay a meaningful dividend and should not be held primarily for income.
09Is INNV or OSCR or ALHC or UNH or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between INNV and OSCR and ALHC and UNH and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: INNV is a small-cap quality compounder stock; OSCR is a small-cap high-growth stock; ALHC is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock. UNH, CVS pay a dividend while INNV, OSCR, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.